Research Study

A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell Transfusion Dependence
Principal Investigator 
Thomas Nevill

Overview

Body Locations and Systems 
Bone Diseases
Disorders and Conditions 
ClinicalTrials.gov# 
NCT01178281
Status 
Closed to Recruitment
Study Start/End 
May 2, 2011 to Dec 31, 2018
Locations 
Vancouver General Hospital
Name/Title 
Lisa Basque, Research Nurse
Phone 
604-875-4111 ext.69014
Email Address 
lbasque@bccancer.bc.ca
Purpose of Study 

The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis. (Global Study) and to describe the frequency of anemia response to pomalidomide in Chinese participants with MPN-associated myelofibrosis and severe anemia not receiving REC-transfusions (China Extension Study only).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.